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Abstract
The immunological risks caused by fibrous and particulate substances, especially the
effects caused by asbestos fibers and silica particles, are discussed in this chapter. Patients
with silicosis often suffer from autoimmune diseases, such as rheumatoid arthritis,
systemic sclerosis, and antineutrophil cytoplasmic antibody–related vasculitis. Silica
particles, SiO2, may influence directly various immune cells resulting in the production
of many autoantibodies and imbalance between responder and regulatory T cells. The
core chemical content of asbestos fibers is Si and O, although the physical feature is
different. Considering the complications in asbestos-exposed patients, malignant tumors,
such as lung cancer and malignant mesothelioma, are the most important. To think about
these situations, asbestos fibers may cause the reduction of antitumor immunity. The
experimental  findings  and measurements  of  various  immunological  parameters  in
silicosis patients, as well as asbestos-exposed population, such as patients with pleural
plaque and mesothelioma, are demonstrated and discussed in this chapter.
Keywords: asbestos, silica, autoimmune diseases, antitumor immunity, regulatory T
cell
1. Introduction
Regarding environmental factors that cause health risks, exposure to fibrous and particulate
substances, such as asbestos fibers and silica particles, represent classic examples, and the
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investigation of other materials that lead to health impairment following exposure is ongoing
[1–10]. In addition to pulmonary effects, such as fibrosis, chronic inflammations, and cancers,
such as lung malignancies and pleural mesothelioma, in asbestos-exposed patients, there may
be certain effects on immunological cells [11–16]. Among people who have been exposed to
asbestos fibers or silica particles, people exposed to silica and have developed silicosis often
suffer from complicated autoimmune diseases, such as rheumatoid arthritis, systemic sclero‐
sis, and antineutrophil cytoplasmic antigen (ANCA)–related vasculitis [17–20]. The core
chemical components of asbestos fibers are Si and O2, and although the physical makeup of
fibrous and particulate matter differs, asbestos fibers may affect the immune system. Therefore,
we have been investigating the immunological effects of silica and asbestos [11–16].
Regarding silica particles, the mechanism of silica-induced dysregulation of autoimmunity is
thought to involve silica acting as an adjuvant [21–24]. However, silica particles may also act
by directly stimulating on circulating peripheral immune cells, which cause certain alterations
in the cellular or molecular functions of these cells, since silica particles may remain in
pulmonary lesions and lymph nodes after inhalation [11–16]. Since these direct effects may
change the characteristics of immune cells and consequently facilitate the dysregulation of
immune tolerance, clarification of these cellular and molecular mechanisms may be useful in
the prevention of immune disorders that occur in silicosis patients (SIL), in addition to
contributing toward an understanding of the etiology of various autoimmune diseases.
We have been focusing on the immunological effects of silica using human peripheral blood
immune cells derived from healthy donors (HD) and SIL [11–14]. We will summarize our
findings which indicate that silica is an environmental immune stimulator, and chronic
activation of immune cells induced by recurrent and chronic exposure to silica causes an
imbalance in the regulation of T cell responses.
Regarding asbestos fibers, asbestos-related cancers, such as malignant mesothelioma (MM)
and lung cancer, have been a major global concern in Japan [25–29]. Given the conflict that has
arisen due to economic considerations and the medical evidence, there is a confusion con‐
cerning the pathological mechanisms of asbestos-induced cancers, and in particular, an
uncertainty concerning the dangers of iron-absent chrysotile (white) asbestos compared with
iron-present crocidolite (blue) and amosite (brown) asbestos [30–33]. However, regarding the
poor prognosis of MM, novel medical approaches to investigate the biological effects of
asbestos and pathological mechanisms of asbestos-induced carcinogenesis, as well as clinical
trials to detect early stages of MM, should be implemented to assist in the development of
improved prevention strategies and cure of asbestos-related malignancies [34–36]. From this
standpoint, our group has been investigating the immunological effects of asbestos with
respect to the reduction of tumor immunity [11, 12, 15, 16]. In this chapter, cellular and
molecular approaches to clarify the immunological effects of asbestos are described, and all
findings indicate that a reduction of tumor immunity is caused by asbestos exposure and is
involved in asbestos-induced cancers. In addition to confirming the well-known biological
effects of asbestos, these investigations provide a basis for the development of a novel
procedure for the early detection of previous asbestos exposure, mesothelioma and the
chemoprevention of asbestos-related cancers.
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As shown in Figure 1, both silica particles and asbestos fibers cause pulmonary fibrosis known
as pneumoconiosis, silicosis, and asbestosis. Additionally, both can affect various immune
cells, such as B cells, CD4 T helper (Th1), regulatory T (Treg), cytotoxic T lymphocyte (CTL),
natural killer (NK) cells, and other immune cells [11, 12, 15, 16].
Figure 1. Schematic representation of immunological risks caused by exposure to silica particles and asbestos fibers.
The immunological risks induced crucial complications, such as autoimmune diseases, in silicosis patients, as well as
malignant tumors, such as lung cancer and malignant mesothelioma, in asbestos-exposed populations.
In this chapter, the immunological effects on various immune cells caused by silica particles
and asbestos fibers as investigated in our laboratory will be presented and discussed with
respect to the detection of immunological risks of particulate and fibrous environmental factors
[11–16]. These summarized findings may be helpful in the development of future risk man‐
agement strategies, including cases related to newly developed fibrous and particulate matter,
such as nanoparticles and nanotubes.
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2. Immunological risks caused by silica particles
As shown in Table 1, there are various immunological risks associated with exposure to silica
particles. These findings were established by in vitro assays using peripheral blood mononu‐
clear cells (PBMC) derived from HD cultured with silica particles as well as freshly isolated
immune cells derived from SIL. Additionally, various autoantibodies (aAbs) were detected
from SIL [11–14]. All SIL comprised Japanese workers of a firebrick factory located at Bizen
City, Okayama Prefecture, Japan, diagnosed with silicosis according to the International Labor
Organization (ILO) 2000 guidelines for pneumoconiosis and monitored at Kusaka Hospital or
Hinase Urakami Iin/Clinic at Bizen City. All SIL showed no symptoms related to autoimmune
diseases or cancers.
Risk manifestation Target cells/molecules Findings References
Unusual autoantibody B cell Detection of autoantibodies against
➢ Fas/CD95 61
➢ Caspase 8 62
➢ Scl-70/Topoisomerase I 56–58
  ♦  Specific HLA type
➢CENP-B/centromere 64
➢Desmoglein 65
Dysregulated apoptosis T cell Increased level of molecules against
Fas-mediated apoptosis
➢ Soluble Fas
  ♦ Serum soluble Fas 69
  ♦ mRNA expression in PBMC 70
➢ Variant Fas, alternatively spliced variants 71
➢ Decoy receptor 3 74
  ♦ mRNA expression in PBMC
Chronic activation 80
➢ Soluble IL-2 receptor 78
➢ PD-1 expression 79
➢ CD69 surface expression
Increase in Fas-mediated apoptosis 61
➢ Autoantibody for Fas 75
➢ Decreased expression of physiological
inhibitors of Fas-mediated apoptosis
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Risk manifestation Target cells/molecules Findings References
Regulatory T cell Chronic activation
➢ Excess expression of Fas/CD95 >78
IL, interleukin; PBMC, peripheral blood mononuclear cells; and PD-1, program death protein 1
Table 1. Immunological risks caused by silica particles.
2.1. aAbs detected in SIL
First, the risk of dysregulated autoimmunity assessed by the detection of particular aAbs will
be discussed. Various aAbs have been detected in SIL, such as antinuclear antibody (ANA)
[37–40], antismooth muscle aAb [41], antiglomerular basement membrane (GBM) aAb [41],
antineutrophil cytoplasmic aAb (MPO-ANCA) [37, 42–48], rheumatoid factor (RF) [37–39, 49–
53], anti-Scl-70/topoisomerase I aAb [37, 54–60], anti-Fas/CD95 aAb [61], anticaspase 8 aAb
[62], anticentromere/CENP-B (centromere protein B) aAb [63], antidesmoglein aAb [64], anti-
PL 12 (aminoacyl tRNA synthetase) aAb [65], and anticollagen aAb [39], as found in publica‐
tions located via PubMed.
Of these aAbs, we investigated several Abs of interest, such as anti-Fas/CD95 Ab [61], anti‐
caspase 8 Ab [62], anti-Scl-70 Ab with respect to specific human leukocyte antigen (HLA) types
[56–58], and anti-CENP-B Ab [63] and reported the case of antidesmoglein Ab-positive SIL [64].
We detected anti-Fas/CD95 aAb in approximately one-fourth of SIL [61]. Since T cells in SIL
tend to be categorized into two classes, Fas/CD95-mediated apoptosis prone and resistant
groups as described later in this chapter, it is important to determine whether the detected
anti-Fas/CD95 aAb is functional in terms of the induction of Fas/CD95-mediated apoptosis. To
examine this issue, we employed our established human sister myeloma cell lines, KMS-12PE
and KMS-12BM. The former cell line was established from the pleural effusion of a myeloma
patient, which showed high expression of Fas/CD95 on its surface as a result of apoptosis and
growth inhibition caused by anti-Fas/CD95 agonistic antibody. The latter cell line was derived
from bone marrow obtained from the same patients, who showed very low expression of Fas/
CD95 and no apoptosis caused by Fas/CD95 agonistic antibody [66]. Following cultivation of
both cell lines with anti-Fas/CD95 aAb-positive serum from SIL, the growth of KMS-12PE was
reduced by apoptosis, whereas the growth of KMS-12BM was unaffected [61]. These results
indicated that anti-Fas/CD95 aAb is functional. Additionally, epitope mapping employing 12-
amino acid polypeptides with the SPOT system of anti-Fas/CD95 aAb was analyzed. As a
result, a minimum of four and a maximum of ten epitopes were found, and several amino acid
residues involved in binding Fas ligand, such as C66, R87, L90 E93, and H126, were identified
[61].
As in the case of anti-Fas/CD95 aAb, anticaspase 8 aAb was investigated in terms of the
dysregulation of Fas/CD95-mediated apoptosis of lymphocytes in SIL [62]. The association of
anticaspase 8 aAb with HLA types was examined. As a result, the frequencies of HLA-
DRB1*0406 were significantly higher in aAb-positive SIL (16.7%) compared with control
individuals (3.0%, p<0.001). Additionally, HLA-DR4; DQB1*0302 was found in one-fourth of
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positive SIL, and DPB1*0601 was also higher in positive SIL (5.9%) compared with controls
(0.6%, p<0.05), whereas DQB1*0401 was lower in positive SIL (0%) compared with controls
(13.3%, p<0.001). Furthermore, epitope mapping showed that a minimum of four and a
maximum of thirteen polypeptides seemed to be involved. Among these, two important
catalytic cysteine residues were found, cysteine Cys287 and Cys360, located in the unique
pentapeptide motif QACQG [62].
Regarding the relationship between aAb and specific HLA type, we reported HLA types
among anti-Scl70/topoisomerase I aAb-positive SIL [56–58]. Results indicated that the allelic
frequency of HLA-DQB1*0402 was significantly higher in aAb-positive SIL (28.6%) than in
aAb-negative SIL (1.5%, p<0.001), as well as in controls (0.8%, p<0.001). Additionally,
DQDB1*0301, DQB1*0601, and DPB1*1801 were higher in aAb-positive SIL than in aAb-
negative SIL, whereas no significant differences were found compared with controls [56–58].
In terms of anti-CENP-B/centromere aAb, the titer index (Log10) of anti-CENP-B autoantibody
in SIL was higher than that of HV, and patients with systemic sclerosis (SSc) was higher than
those of HV and SIL. This titer index was positively correlated with an assumed immune status
for HV as 1, SIL as 2, and SSc as 3. Moreover, although the titer index of anti-CENP-B auto‐
antibody formed the same factor with anti-Scl-70 autoantibody, the Ig G value, and age of SIL,
the property of other factors extracted indicated that anti-Scl-70 antibody was positively
related with the Ig A value, while the converse was true for anti-CENP-B from the results of
factor analysis. Those results indicated that the titer index of anti-CENP-B autoantibody may
be employed as a biomarker in identifying dysregulation in SIL cases.
Taken together, various aAbs found in SIL have indicated that dysregulation of autoimmunity
was caused by chronic and recurrent exposure to silica particles that remained in lung and
related lymph nodes of various human cells, especially B cells. Some of these aAbs may be
related to Fas/CD95-mediated apoptosis of lymphocytes and cause further dysregulation of
autoimmunity such as in the case of long-surviving self-antigen recognizing clones in T cells
[11–14].
Furthermore, examination of HLA types seemed to be important in revealing several aAbs in
SIL. Although it can be mentioned that repeated and continuous screening of aAbs as well as
the initial screening of HLA types seems to be necessary among workers in contact with silica-
related substances for the detection of dysregulation of autoimmunity, the use of genotyping,
such as determining HLA types, is not permitted during employee selection procedures.
However, a consideration of particular occupational health risks together with individual
sensitivities is required in an effort to prevent occupational health hazards and associated
future hardships.
2.2. Fas/CD95-mediated apoptosis–related molecules in SIL
Fas/CD95-related molecules analyzed in SIL are shown in Table 1 [11–14, 67]. Regarding
molecules that inhibit Fas/CD95-mediated apoptosis, the level of soluble Fas/CD95 was higher
in the serum of SIL compared with HD, and similar to the level in systemic lupus erythema‐
tosus (SLE) [68], while higher mRNA expression, determined as the ratio of soluble to wild-
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type Fas/CD95, was present in SIL compared with HD in PBMC [69]. Additionally, higher
amounts of various alternatively spliced variant messages of the Fas/CD95 gene were detected
in PBMC from SIL compared with HD [70]. All of these variant messages, including soluble
Fas/CD95, possess a Fas ligand-binding domain but lack a membrane-binding domain. Hence
all of these translation products are secreted into the extracellular space and bind with Fas
ligand, thereby protecting cells against membrane Fas-mediated apoptosis [70]. Furthermore,
the expression of the protective molecule decoy receptor 3 (DcR3), which acts against the Trail
molecule and similarly induces apoptosis via a Trail receptor and the same intracellular
signaling molecules for apoptosis, such as caspase 8 and 10 [71, 72], was higher in SIL PBMC
compared with HD [73]. These findings indicated that some types of T cells in PBMC from SIL
provide protection against Fas/CD95- and Trail-induced apoptosis, which leads to long
survival of these T cells and self-antigen recognizing clones [67].
However, several findings that showed accelerated Fas/CD95- and Trail-mediated apoptosis
in PBMC of SIL were investigated. Messenger RNA expression in PBMC of several genes which
act as physiological inhibitors of Fas/CD95- and Trail-mediated apoptosis, such as I-Flice
(inhibitor of FADD-like interleukin-1β–converting enzyme), surviving, sentrin, and inhibitor
of caspase-activated DNase (ICAD) was lower in SIL compared with HD [67, 74]. In addition
to the aforementioned detection of functional anti-Fas/CD95 autoantibody, some types of T
cells in PBMC from SIL possess enhanced Fas/CD95-mediated apoptosis [61]. Further studies
revealed that this fraction may include Treg cells [13, 14]. Thus, a decrease in the number of
Treg cells by apoptosis and an increase in the number of responder T cells caused by silica
exposure may be the cellular biological mechanisms at work in SIL, which consequently impart
susceptibility to autoimmune diseases in SIL.
We found higher expression of Fas/CD95 in Treg (CD4+, CD25+, and forkhead box P3 (FoxP3)
+) [75, 76] and sensitivity to Fas-agonistic antibody–induced apoptosis in Treg cells from SIL
[77]. Furthermore, when PBMC from HD were cultured with silica particles in vitro, Treg cell
numbers were selectively reduced by apoptosis and the population of responder T cells was
enhanced [77]. Thus, the aforementioned T cell population prone to Fas/CD95-mediated
apoptosis seems to comprise Treg cells, and the imbalance that occurs as a result of a decreased
Treg and surviving responder T cell population in SIL induces dysregulation of autoimmunity
[13, 14, 77].
Moreover, there is evidence showing chronic activation of responder T cells. For example,
CD69, an early activating marker of T cells, was gradually expressed in T cells when PBMC
from HD were cultured in vitro with silica particles [78]. Expression of the program death
protein 1 (PD-1) gene, another activation marker of T cells, in CD4+ CD25+ as well as in CD4+
CD25− T cell populations was higher in SIL compared with HD, which showed negligible
expression [78]. Expression of serum soluble interleukin (IL)-2 receptor (sIL-2R) was also
higher in SIL compared with HD [79].
Taken together, SIL possess a risk of developing dysregulation of autoimmunity. This risk can
be detected using various markers mentioned above, such as serum soluble Fas, sIL-2R, and
serum DcR3 (recently, the enzyme-linked immunosorbent assay (ELISA) kit is available for
laboratory use), in SIL during their early clinical phases.
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3. Immunological risks caused by asbestos fibers
As shown in Figure 1, the most important and critical complications that arise in asbestos-
exposed patients concern the development of malignancies, such as lung cancer and MM [25–
29]. Of course, asbestos fibers possess carcinogenic-related activities, such as oxygen stress
caused by iron in the asbestos fibers, frustrated macrophages incapable of phagocytosing
asbestos fibers, chromosome tangling, and the absorption of other carcinogenic substances
inhaled in the lung, such as materials from tobacco smoke and other air pollutants [34–36].
However, given the long latency period that precedes the onset of MM following initial
exposure to asbestos, it was considered that asbestos fibers cause alterations in antitumor
immunity by recurrent and chronic encounters with various immune cells at the lung and
related lymph nodes.
As shown in Table 2, our findings show altered immune cell function and manifestations from







Innate Immune system NK cells Reduction of cytotoxicity
➢ Freshly isolated NK cells
 ♦ NK cells from asbestos-exposed patients (PP and MM) 83–84
 ♦ NK cells from HD stimulated in vitro with 83
   asbestos 83
➢ Human cell line cultured with asbestos
Reduced expression of NK cell activation receptor 83
➢ Human cell line cultured with asbestos: NKG2D, 2B4 83,84
➢ Freshly isolated NK cells
 ♦ NK cells from asbestos-exposed patients (PP and MM): NKp46 83,84
 ♦ NK cells from HD stimulated in vitro with asbestos: NKp46 84
Reduction of phosphorylation of ERK 1/2
➢ Human cell line cultured with asbestos
MHC class I restricted
killing System
CTLs Suppressed differentiation and proliferation
➢ In vitro assay using MLR with asbestos 85
Alteration of killing molecules (granzyme B, IFNγ, perforin)
➢ In vitro assay using MLR with asbestos 86
➢ Freshly isolated and in vitro stimulated peripheral






  CD8+ cells from PP 86
➢ Freshly isolated and in vitro stimulated peripheral
  CD8+ cells from MM
MHC class II restricted
killing system
Th1 cells Decrease in CXCR3 expression, IFNγ
➢ Cell line model continuously cultured with
asbestos
87
➢ Freshly isolated and cultured in vitro with
asbestos from HD
88







➢ Cell line model continuously cultured with asbestos
 ♦ Increased suppressive function via cell-cell contacts 91
 ♦ Excess production of soluble factors
  ✓  IL-10 91
   ✕ Enhanced suppressive function 89
   ✕  Phosphorylation of STAT3 with over-expression of
Bcl-2 causing resistance against asbestos-induced apoptosis
  ✓ TGFβ 91
   ✕ Enhanced suppressive function 90
   ✕ Increased phosphorylation of p38 and SMAD3 causing
resistance against TGFβ-induced growth inhibition
CXCR3, CXC chemokine receptor 3; HD, healthy donor; IFN, interferon; IL, interleukin; MLR, mixed lymphocyte
reaction; MM, malignant mesothelioma; NK, natural killer; PP, pleural plaque; TGF, transforming growth factor;
SMAD, vertebrate homologues of Sma and Mad [Drosophila protein; mothers against decapentaplegic (MAD) and the
Caenorhabditis elegans protein SMA (from the sma gene for small body size)]; and Th1, T helper.
Table 2. Immunological risks caused by asbestos fibers.
3.1. NK cells
Regarding NK cells, cytotoxicity was reduced in peripheral NK cells from pleural plaque (PP)
and MM, in NK cells from HD cultured in vitro with asbestos fiber, and in a human NK cell
line continuously exposed to asbestos [82]. Additionally, the expression of various NK cell
activating receptors, such as NKG2D, 2B4, and NKp46, was reduced in a human NK cell line
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cultured continuously with asbestos, in freshly isolated NK cells from HD cultured in vitro
with asbestos, and in fresh NK cells from PP and MM [82, 83]. Among these receptors, NKp46
was thought to be an important marker for impaired function of NK cells exposed to asbestos.
Moreover, reduced cytotoxicity in NK cells exposed to asbestos was accompanied with
reduced phosphorylation of extracellularly regulated kinases (ERK) 1 and 2 and reduced
degranulation of perforin and granzyme B, which are the killing small molecules secreted from
NK cells [82, 83].
3.2. Cytotoxic T lymphocytes
Other types of cytokilling immune cells, CTLs, are also involved and have their functional and
cellular properties altered by asbestos exposure. From in vitro analyses using peripheral CTLs
in a mixed lymphocyte reaction (MLR), it was found that differentiation and proliferation of
CD8+ naïve T cells were disturbed by the presence of cocultured asbestos fibers with decreased
expression of killing small molecules, such as granzyme B and interferon γ (IFNγ) [84].
Moreover, alteration of killing molecules, as well as the phenotype of CD8+ cells, was mani‐
fested by CD45RA as the marker of effector/memory T cells. Freshly isolated CD8+ cells
derived from asbestos-exposed patients, such as PP and MM, showed a higher predominance
of CD45RA-negative cells compared with HD [85]. However, the cytokilling activity differed
between isolated and in vitro-stimulated CD8+ cells. CD8+ cells from PP and MM revealed an
increase in the number of perforin-positive cells; however, after in vitro stimulation, only CD8+
cells from MM showed a decrease in the perforin-positive cell population when subtracted
from the unstimulated base line [85].
These findings indicated that asbestos exposure caused dysfunction of CTLs, while specific
cell functions differed depending on disease status, for example, PP patients do not carry any
malignant tumors, whereas MM patients suffer from mesothelioma. However, the impact of
asbestos fibers on CTLs is considered to involve a reduction of tumor immunity, as we showed
in NK cells mentioned above [84, 85].
3.3. Th 1 cells
Asbestos fibers are also known to modify Th1 cells. We developed continuously exposed
sublines using a cell line model. The cDNA microarray data were examined of the original cell
line, which has had no contact with asbestos fibers, and six independently established sublines,
which were continuously exposed to asbestos fibers for more than 8 months using an asbestos
concentration that did not induce apoptosis in more than half of the cells by transient exposure.
The microarray showed a decrease in IFNγ and related molecules, such as IFN regulatory
factor 9 (IRF9) and IFN-stimulating gene factor-3 (ISGF3), in addition to a decrease in CXC
chemokine receptor 3 (CXCR3), which is regulated by IRF9 [86].
CXCR3 is important in antitumor immunity to summon IFNγ-positive tumor antigen recog‐
nizing Th1 cells to the tumor. Thus, the asbestos-induced reduction of CXCR3 and IFNγ seems
to cause a reduction of antitumor immunity in asbestos-exposed patients. As we assumed,
examination of freshly isolated CD4+ cells from HD stimulated in vitro and cocultured with
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asbestos fibers as well as peripheral CD4+ cells from PP and MM revealed a decrease in the
cell surface expression of CXCR3 in addition to a decrease in the number of intracellular IFNγ-
positive cells [87].
Taken together, one of the immunological risks resulting from asbestos exposure concerns a
reduction of Th1-type T cell–derived antitumor immunity.
3.4. Treg cells
Treg cells are important in antitumor immunity. If the function and number of Treg cells are
enhanced, immune cells responding to tumor antigen show suppressed function, which causes
a reduction of antitumor immunity [75, 76].
Our cell line model continuously exposed to asbestos fibers using MT-2, a human T-lympho‐
tropic virus type 1, which causes adult T cell leukemia/lymphoma, showed excess production
of transforming growth factor (TGF) β and IL-10, typical soluble factors examined to reveal
the function of Treg cells [88, 89]. Overproduction of IL-10 is regulated by the Src-family
receptor and is used by the IL-10 receptor via autocrine mechanisms, which then causes
activation of the signal transducer and activator of transcription 3 (STAT 3) and upregulation
of antiapoptotic molecule Bcl-2 located downstream of STAT3 [88]. Continuously exposed
sublines acquire resistance to apoptosis induced via transient exposure to asbestos [88].
Furthermore, overproduction of TGFβ induces resistance to TGFβ-induced growth inhibition
in continuously exposed sublines with phosphorylation of p38, one of the signaling molecules
in the mitogen-activated protein kinase (MAPK) signaling pathway, as well as phosphoryla‐
tion of SMAD3 [SMAD; vertebrate homologues of Sma and Mad [Drosophila protein, mothers
against decapentaplegic (MAD) and the Caenorhabditis elegans protein SMA (from the sma
gene for small body size)] [89].
In addition to the two aforementioned typical soluble factors, continuous exposure of MT-2
sublines to asbestos resulted in markedly higher suppressive activity when mixed with
cultures of CD4+ responder cells activated with anti-CD3 antibody and autologous peripheral
blood monocyte-derived dendritic cells compared with the original MT-2 cell line, which has
had no contact with asbestos [90].
Taken together, exposure to asbestos results in enhanced Treg function, which is manifested
by a reduction of antitumor immunity [11, 12, 15, 16, 80, 81].
3.5. Risks of asbestos on antitumor immunity
As mentioned above and shown in Table 2, all of the examined effects of asbestos on NK cells,
CTLs, Th1, and Treg cells indicate that asbestos exposure can cause a reduction of antitumor
immunity. These findings are considerable and the risks associated with asbestos exposure
may be used as early detection markers for the occurrence of asbestos-induced malignancies.
Additionally, the ability to mitigate the observed reduction of antitumor immunity through
the use of chemopreventive substances derived from foods or plants may be an important
strategy in the treatment of high-risk groups exposed to asbestos, such as residents who have
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a history of living near factories handling asbestos and workers in the building demolition and
rubble processing fields.
4. Conclusion
Risks associated with exposure to fibers, such as asbestos, and particulates, such as silica, were
discussed based on our experimental findings and analyzed using cell lines, freshly isolated
peripheral immune cells from HD, as well as patients exposed to silica particles, exposed to
asbestos fibers, and patients with silicosis, PP, and MM. The immunological risks manifested
in different directions, in that silica caused dysregulation of autoimmunity, whereas asbestos
induced a reduction of antitumor immunity. Both cellular and molecular alterations contrib‐
uted to the complications of silica exposure, the occurrence of autoimmune diseases and
asbestos exposure, and the development of malignant tumors.
These risks may be detected using findings described in this chapter, and early detection of
these risks may assist workers, as well as other exposed populations, in avoiding further
exposure and therefore prevent the onset of various pathological states caused by exposure to
fibrous and particulate substances. Recently, although exposure to silica and asbestos has been
reduced through the improvement of work-related environments as well as banning the use
of asbestos, new substances, such as nanomaterials, which are widely used in the industrial
fields, are now feared to cause health risks. It should be reiterated that risks, and particularly
immunological ones which hitherto have not received a great deal of attention, caused by
classical types of particulate and fibrous substances, such as silica and asbestos, require
continued and greater consideration in an effort to further prevent the health impairment
caused by environmental substances.
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